Researchers at the Earlham Institute, the University of Edinburgh and Heriot-Watt University analyzed gut cells to understand the drivers behind fibrosis, a common complication in Crohn's disease ...

NFL quarterback Boomer Esiason and his son, Gunnar, were thrust into the spotlight in 1993 when Gunnar was diagnosed with cystic fibrosis, then a little-known disease that was viewed as a fatal ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Predicted survival has gone up from 46 years in 2015 to ...

Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis (MASH) could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is a new oral medicine approved to treat idiopathic pulmonary fibrosis (IPF) in adults. IPF is a rare and serious condition that causes ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

Their research led to the development of a drug that nearly doubles the life expectancy for adult cystic fibrosis patients Three scientists who revolutionized the treatment of cystic fibrosis and ...

The scientific imperative to identify drugs that could repair mutant CFTR presented a formidable challenge. Small molecules that specifically bound and repaired a defective CFTR peptide fold were ...

One of this year's coveted Lasker Awards went to three scientists who helped invent a life-saving treatment for cystic fibrosis, a genetic disease. When you purchase through links on our site, we may ...

Three scientists who revolutionized the treatment of cystic fibrosis and prolonged the lifespan of patients with the deadly disease have won the Lasker Award, one of the most prestigious awards in ...

Resolution of steatohepatitis with no worsening of liver fibrosis was achieved in 63% of patients taking semaglutide vs 34% taking placebo at week 72. The Food and Drug Administration (FDA) has ...

On Friday, the FDA granted accelerated approval to Novo Nordisk’s Wegovy for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis but without ...